-
July 22, 2022 A Big Week for Psychedelic Stocks: 2 CEOs Step Down, MDMA Patents and a Phase 3 TrialCompass Pathways and Small Pharma announce executive shakeup, Mydecine and Awakn push forward with new...
-
July 19, 2022 Compass Pathways Appoints a New CEOGeorge Goldsmith will be replaced as Compass Pathways CEO. Is this good or bad news?
-
June 24, 2022 Compass Pathways Psilocybin Patent UpheldCompass Pathways scores a major victory in their bid to patent Comp 360, a proprietary...
-
May 17, 2022 Comparing MindMed, Atai Life Sciences, Compass Pathways: A Psychedelic Stock AnalysisOur resident psychedelic investor explains a handful of important metrics to study when analyzing and...
-
May 6, 2022 Psychedelic Business Spotlight – May 6This week in psychedelic business news: Wesana Health pivots strategy; Compass Pathways makes progress on...
-
May 5, 2022 Compass Pathways Shares ‘Promising’ Data That Psilocybin May Treat AnorexiaThere is currently no FDA-approved treatment for anorexia. Could psychedelics be the answer?
-
April 21, 2022 Kevin O’Leary Predicts These 3 Psychedelic Companies Will Merge, But Should They?Our resident Psychedelic Investor James Hallifax wonders if the "Shark Tank" star's prediction makes financial...
-
March 30, 2022 5 Most Important Psychedelic Clinical Trials in 2022Here's why we think MAPS’ second Phase 3 MDMA trial is the most important psychedelic...
-
March 25, 2022 Psychedelic Business Spotlight – March 25This week in psychedelic business news: Filament Health scores 2nd psilocybin patent; a new psychedelics...
-
March 15, 2022 Top 5 Most Influential Psychedelic StudiesWe unpack five of the most important psychedelic studies conducted in recent years as psychedelics...
